Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Less-invasive BPH (benign prostatic hyperplasia) treatment cleared for US sale:

This article was originally published in Clinica

Executive Summary

The US FDA has cleared for sale Gyrus' Endourology system, which uses PlasmaKinetic radiofrequency technology to remove part of the prostate in patients with benign prostatic hyperplasia. The system is the third using PlasmaKinetic technology to be cleared by the FDA - the VAPR arthroscopy device and the VersaPoint hysteroscopic system are already sold in that market. The Cardiff, UK-based company now plans to begin discussions with potential US distributors for the Endourology system.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT078903

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel